Conexeu Sciences Inc., a biotechnology company specializing in regenerative medicine, printed bovine-derived collagen-based scaffolds using its CXU biolink platform. The next phase before potentially rolling out to areas of medicine like aesthetics and surgery for wound healing and tissue regeneration, is clearance from the FDA.
Conexeu intends to use the CXU collagen platfrom, an extracellular matrix, as a foundation for personalized tissue regeneration in the future, particularly focusing on three domains: personalized implants and grafts, vascular-supportive microenvironments and biofabrication in medicine. Personalization, according to a Nov. 20 press release, involves craniofacial, breast, periodontal and soft-tissue reconstruction, printed to match the patient.
The vascular-supportive microenvironments provide the scaffolding that helps new blood vessels grow—an essential factor in keeping cells alive. CXU, per the release, functions as an injectable regenerative device and a printable ECM bioink. If cleared for commercialization, the scaffold could have relevance in wound care, aesthetics, dental, reconstructive surgery and 3D bioprinting.
"By showing that CXU can print tissue structures, we are opening the door to truly personalized implants and grafts,” said Claudia Chavez-Munoz, MD, PhD, Chief Science Officer of Conexeu. “If cleared by the FDA, this will place CXU at the forefront of all bioinks, being the first collagen-based extracellular matrix medical grade in the market."
This jumpstart to potential clearance follows the company reaching its goal of collecting 5 million in crowdfunding in October to accelerate the development and commercialization of CXU collagen platform.
